Search
Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalIt was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences. … [L34319] The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but are more sensitive and can reveal cancerous tissue in any area of the body provided
Oxaliplatin
go.drugbank.com/drugs/DB00526ApprovedInvestigationalOxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. … [A797] Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics.
Synonyms: (SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUMFenfluramine
go.drugbank.com/drugs/DB00574ApprovedIllicitInvestigationalWithdrawnIt is currently sold under the name FINTEPLA® by Zogenix INC.[L14522] … It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression.
Levofloxacin
go.drugbank.com/drugs/DB01137ApprovedInvestigational[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663] … carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin[A190663] and remains stereochemically stable following administration (i.e. it does not
Sodium glycerophosphate
go.drugbank.com/drugs/DB09561ApprovedIt is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667].
Mixtures: SmofKabiven Low Osmo peripher Emulsion zur Infusion, OLICLINOMEL N4-550 E EMULSION FOR INFUSIONOdesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high
Leucovorin
go.drugbank.com/drugs/DB00650ApprovedInvestigational[L56092, A257419] Unlike folic acid, leucovorin does not require the enzyme dihydrofolate reductase (DHFR) for activation, allowing it to function even when DHFR is inhibited by drugs like methotrexate … -fluorouracil (5-FU) to enhance therapeutic efficacy in the palliative treatment of advanced colorectal cancer and to treat megaloblastic anemias resulting from folate deficiency when oral therapy is not
Synonyms: N5-Formyltetrahydrofolic acid, N5-Formyl-5,6,7,8-tetrahydrofolic acidDeucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity
Tyrosine-protein phosphatase non-receptor type 11
go.drugbank.com/bio_entities/BE0001071TargetHumansActs downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus (PubMed:10655584, PubMed:14739280, PubMed:18559669, PubMed:18829466, PubMed:26742...
Polypeptides: Tyrosine-protein phosphatase non-receptor type 11Non-selective voltage-gated ion channel VDAC1
go.drugbank.com/bio_entities/BE0002468TargetHumansNon-selective voltage-gated ion channel that mediates the transport of anions and cations through the mitochondrion outer membrane and plasma membrane (PubMed:10661876, PubMed:11845315, PubMed:18755977
Polypeptides: Non-selective voltage-gated ion channel VDAC1